Glucagon vs Insulin: In-depth Analysis of Peptide Category Comparison
Published: July 15, 2026 04:32
Author: Robert Cannon
Abstract: This analysis compares glucagon and insulin as peptide therapeutics, highlighting their distinct mechanisms in glucose regulation. Market data indicates insulin dominates a $50B+ sector, while glucagon is niche but growing for hypoglycemia. Insulin brands (Novo Nordisk, Eli Lilly) offer superior stability and delivery, whereas glucagon’s rapid action limits formulation. Key parameters: insulin’s half-life (4-6h) vs glucagon’s (3-6min). Both require cold-chain logistics and GMP-certified facilities. Selection criteria prioritize purity (>98%) and bioactivity. Industry trends show rising demand for dual-action analogs, with regulatory compliance (FDA/EMA) critical for market entry.